Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA
Scott K. Heysell , Jane L. Moore, Suzanne J. Keller, and Eric R. Houpt
Author affiliations: Author affiliations: University of Virginia, Charlottesville, Virginia, USA (S.K. Heysell, E.R. Houpt); Virginia Department of Health, Richmond, Virginia, USA (J.L. Moore, S.J. Keller)
Figure 2. Results in patients with initial serum concentrations 2 h after medication below the expected range with follow-up levels after dose adjustment for rifampin daily or biweekly (A), isoniazid daily (B), and isoniazid biweekly (C). The median initial and follow-up doses of rifampin daily or biweekly were 600 mg and 900 mg, respectively; for isoniazid daily, 300 mg and 450 mg, respectively; and for isoniazid biweekly, 900 mg and 1,200 mg, respectively. Brackets represent expected ranges for each dose of medication.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.